New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 3, 2014
09:56 EDTPRXL, STBZ, ERIC, PE, AERI, STLOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Aerie Pharmaceuticals (AERI) initiated with a Buy at Canaccord... Alliance Fiber Optic (AFOP) initiated with a Buy at Sidoti... Ericsson (ERIC) initiated with a Hold at Jefferies... PAREXEL (PRXL) initiated with a Hold at KeyBanc... Parsely Energy (PE) initiated with a Sector Perform at RBC Capital... State Bank Financial (STBZ) initiated with a Buy at Wunderlich... Sterling Bancorp (STL) initiated with an Outperform at Raymond James.
News For AERI;ERIC;PRXL;PE;STBZ;STL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 3, 2015
08:13 EDTERICEricsson and ABB sign strategic alliance
Subscribe for More Information
05:28 EDTERICEricsson selected as managed services partner for Orange operations
Subscribe for More Information
March 2, 2015
16:08 EDTAERIAerie Pharmaceuticals reports Q4 EPS (69c), consensus (46c)
Subscribe for More Information
09:08 EDTSTBZState Bank and Trust acquires assets of Boyett Agency, terms not disclosed
Subscribe for More Information
05:41 EDTERICBharti Airtel signs two year extension to its existing deal with Ericsson
Subscribe for More Information
05:40 EDTERICEricsson completes trial of Targeted App Experience with SmarTone
Subscribe for More Information
February 27, 2015
05:26 EDTERICEricsson files lawsuits against Apple
Subscribe for More Information
February 26, 2015
16:53 EDTPEParsley Energy reports Q4 EPS ex-items 2c, consensus 9c
Reports Q4 revenue $78.1M, consensus $88.64M. Parsley has issued 2015 production guidance of 18.0-19.0 MBoe/d, representing 30% growth at the midpoint relative to 2014 average daily production of 14.2 MBoe/d. The outlook for 2015 incorporates the effect of winter storms that hindered drilling and production in January. In 2015, the company plans to spend between $195M-$210M on drilling and completion activities and between $30M-$40M on infrastructure and other items, representing total development capital expenditures of $225M-$250M.
11:03 EDTERICSamsung ranks first in 2014 EU patent applications
The European Patent Office reports that Samsung (SSNLF) was ranked first in number of European patent applications for 2014 with 2,541 applications filed. Philips (PHG) took second place with 2,317, Siemens (SIEGY) took third with 2,133, BASF (BASFY) took sixth with 1,530, Qualcomm (QCOM) took seventh with 1,459, Ericsson (ERIC) took ninth with 1,347, and Intel (INTC) took 10th with 1,054 applications filed.
07:21 EDTSTLKeefe Bruyette to hold a conference
Subscribe for More Information
February 24, 2015
07:31 EDTAERIRBC Capital to hold a conference
Subscribe for More Information
05:14 EDTERICEricsson, Leiga Warszawa announces six-year connectivity agreement
Ericson announces a service contract with Leiga Warszawa Municipal Stadium. The six-year agreement will ensure that visitors to the municipal stadium in Warszawa can enjoy carrier-grade Wi-Fi connectivity and value-added services accessible via a mobile app.
February 18, 2015
10:42 EDTERICEricsson to hold a briefing
Chief Marketing & Communications Officer Norrman provides information on the company's participation at Mobile World Congress 2015 on an industry analyst telebriefing to be held on February 19 at 11 am. Webcast Link
08:21 EDTERICBofa European telecom equipment analysts hold analyst/industry conference call
Subscribe for More Information
06:04 EDTAERIAerie Pharmaceuticals' Rhopressa shows positive preliminary evidence in glaucoma
Aerie Pharmaceuticals announced potentially breakthrough findings from new preclinical research indicating that Aerie’s lead drug candidate, Rhopressa, may block the effect of fibrosis-promoting proteins on cells of the trabecular meshwork, a tissue that helps maintain normal pressure in the eye. Fibrosis at the trabecular meshwork is associated with elevated intraocular pressure in patients with glaucoma. This is the first study to show that Rhopressa, a novel once-daily, triple-action eye drop that lowers IOP in glaucoma patients, has the potential to modify the course of the disease by arresting fibrosis. Pending successful advancement of the Phase 3 registration studies, three-month efficacy results are expected in the middle of Q2. If the trials are successful, the company expects to submit a New Drug Application filing by mid-2016.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use